RVL Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2022
RVL Pharmaceuticals plc (Nasdaq: RVLP), a specialty pharmaceutical company, announced its participation in the Barclays Global Healthcare Conference 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RVL Pharmaceuticals plc (Nasdaq: RVLP), a specialty pharmaceutical company, announced its participation in the Barclays Global Healthcare Conference 2022. Key executives, including CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn, will present on March 16, 2022, at 11:15 a.m. ET. The presentation will be available via a webcast, accessible on the company’s website afterward. RVL focuses on developing products for underserved patient populations, with a subsidiary dedicated to ophthalmic and medical aesthetics.
Details
News Market Reaction – RVLP
The recorded move for RVLP in the trading session of this news was -1.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief Financial Officer, will present at the Barclays Global Healthcare Conference 2022, as follows:
| Date: Time: Webcast: | Wednesday, March 16, 2022 11:15 a.m. ET https://cc.webcasts.com/barc002/031522a_js/?entity=85_1GFQ11B |
The webcast will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section.
About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc (Nasdaq: RVLP) is a specialty pharmaceutical company focused on the development and commercialization of products that target markets with underserved patient populations. RVL Pharmaceuticals, Inc., is the Company’s ophthalmic and medical aesthetics subsidiary supporting UPNEEQ®.
Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.